GSK Logo


Are you a Healthcare Professional? Visit the Healthcare Professional website.


Human Papillomavirus vaccine [Types 16, 18]

Product Overview

What is Cervarix

Cervarix is a vaccine intended to protect females against the diseases caused by infection with Human Papillomavirus types 16 and 18.

These diseases include:

  • Cervical cancer (cancer of the lower part of the uterus or womb) and
  • Precancerous lesions of the female genitals (changes in cells of the cervix, vulva and vagina that have a risk of turning into cancer).

How does Cervarix work:

  • Cervarix works by causing the body’s own defences to make antibodies against Human Papillomavirus types 16 and 18.
  • Cervarix will not protect against all types of Human Papillomavirus; types 16 and 18 are responsible for approximately 70% of cervical cancer cases and 70% of HPV-related pre-cancerous lesions of the vulva and vagina.
  • Cervarix vaccine is not infectious and cannot cause the diseases related to Human Papillomavirus infections.

How is Cervarix given:

  • Cervarix is given as an injection into the muscle of the upper arm.
  • A complete course of Cervarix consists of 3 doses, the first given on an agreed date and the second and third given 1 and 6 months later.
  • Cervarix is intended for use in females from 9 years of age onwards.

For further information on Cervarix please see:

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at By reporting side effects you can help provide more information on the safety of this medicine.
Cervarix is a trade mark of the GlaxoSmithKline group of companies.

Rate the usefulness of this page

Rollover stars, click to select, then press submit.

Y.V: Last updated 18 April 2013: UK/CER/0003/13

Links & Resources

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.